- NCIt
- C7480
Loading cancer entity…
Loading cancer entity…
Clinical trials
744 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02046421 | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 31 | University of ChicagoOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT00856180 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 |
| clinicaltrials |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT00230542 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 2 | 44 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00268918 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00520013 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00114166 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 81 | Gynecologic Oncology GroupNETWORK | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00459290 | Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00569673 | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 71 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01652079 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | completed | Phase 2 | 63 | Massachusetts General HospitalOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01295489 | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | — | 39 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT02275039 | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00428610 | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 19, 2018 | clinicaltrials |
| NCT01080521 | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | completed | — | 247 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT00880360 | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer(ONTAK) | completed | Phase 2 | 19 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 27, 2018 | clinicaltrials |
| NCT01219777 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | completed | Phase 1 | 9 | Ritu SalaniOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00499252 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00293293 | Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine | completed | N/A | 43 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00381888 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | completed | Phase 2 | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01105650 | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | completed | Phase 2 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 1 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00334893 | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01582906 | A Survivorship Care Plan for Gynaecological Cancer Patients | completed | — | 150 | Royal Marsden NHS Foundation TrustOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT00857545 | OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission | completed | Phase 2 | 171 | Gynecologic Oncology GroupNETWORK | 1 | Sep 13, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01905163 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients(CILOVE) | completed | Phase 2 | 47 | Centre Jean PerrinOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02343510 | Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study | completed | — | 70 | Ain Shams UniversityOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT00061308 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Jun 9, 2017 | clinicaltrials |
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT00157573 | GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer | completed | Phase 2 | 72 | Massachusetts General HospitalOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT01416038 | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 19 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Apr 21, 2017 | clinicaltrials |
| NCT02311907 | Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | completed | Phase 3 | 195 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT02262455 | Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 32 | Santa Maria BiotherapeuticsINDUSTRY | 1 | Feb 13, 2017 | clinicaltrials |
| NCT01308944 | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00872989 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 129 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 19, 2016 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 11, 2018source: clinicaltrials